Oxford Genetics, MeiraGTx in Gene-Therapy Supply PactBy
Oxford Genetics, an Oxford, England-headquartered synthetic biology-based technology company, has signed an agreement with MeiraGTx, a London, UK-based clinical-stage gene therapy company, to develop adeno-associated virus (AAV) vectors as well as packaging and producer cell lines.
The companies aim to create a fully scalable AAV production system that can satisfy the requirements for increased viral vector yields, process robustness, and product efficacy.
As part of the agreement, MeiraGTx gains exclusive, worldwide research, and manufacturing rights to serotype-specific AAV vectors, along with associated packaging and producer cell lines.
Source: Oxford Genetics